{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:55:09Z","timestamp":1792086909548,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00083"],"award-info":[{"award-number":["PI19\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI20\/00184"],"award-info":[{"award-number":["FI20\/00184"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00556"],"award-info":[{"award-number":["PI22\/00556"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00291"],"award-info":[{"award-number":["CB16\/12\/00291"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3778"],"award-info":[{"award-number":["B2017\/BMD-3778"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3778"],"award-info":[{"award-number":["B2017\/BMD-3778"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3778"],"award-info":[{"award-number":["B2017\/BMD-3778"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["B2017\/BMD-3778"],"award-info":[{"award-number":["B2017\/BMD-3778"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Classic Hodgkin lymphoma (cHL) is characterized by a rich immune microenvironment as the main tumor component. It involves a broad range of cell populations, which are largely unexplored, even though they are known to be essential for growth and survival of Hodgkin and Reed\u2013Sternberg cells. We profiled the gene expression of 25 FFPE cHL samples using NanoString technology and resolved their microenvironment compositions using cell-deconvolution tools, thereby generating patient-specific signatures. The results confirm individual immune fingerprints and recognize multiple clusters enriched in refractory patients, highlighting the relevance of: (1) the composition of immune cells and their functional status, including myeloid cell populations (M1-like, M2-like, plasmacytoid dendritic cells, myeloid-derived suppressor cells, etc.), CD4-positive T cells (exhausted, regulatory, Th17, etc.), cytotoxic CD8 T and natural killer cells; (2) the balance between inflammatory signatures (such as IL6, TNF, IFN-\u03b3\/TGF-\u03b2) and MHC-I\/MHC-II molecules; and (3) several cells, pathways and genes related to the stroma and extracellular matrix remodeling. A validation model combining relevant immune and stromal signatures identifies patients with unfavorable outcomes, producing the same results in an independent cHL series. Our results reveal the heterogeneity of immune responses among patients, confirm previous findings, and identify new functional phenotypes of prognostic and predictive utility.<\/jats:p>","DOI":"10.1038\/s41598-024-51376-1","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T07:02:36Z","timestamp":1704524556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma"],"prefix":"10.1038","volume":"14","author":[{"given":"Victoria","family":"Men\u00e9ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Sol\u00f3rzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Alonso-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cereceda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalb\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Piris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"11","key":"51376_CR1","doi-asserted-by":"publisher","first-page":"e27307","DOI":"10.1002\/pbc.27307","volume":"65","author":"M Henry","year":"2018","unstructured":"Henry, M., Buck, S. & Sava\u015fan, S. Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma. Pediatr. Blood Cancer 65(11), e27307 (2018).","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"51376_CR2","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cancers14051360","volume":"14","author":"V Men\u00e9ndez","year":"2022","unstructured":"Men\u00e9ndez, V., Sol\u00f3rzano, J. L., Fern\u00e1ndez, S., Montalb\u00e1n, C. & Garc\u00eda, J. F. The hodgkin lymphoma immune microenvironment: Turning bad news into good. Cancers 14(5), 1360 (2022).","journal-title":"Cancers"},{"issue":"10","key":"51376_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N. Engl. J. Med. 362(10), 875\u2013885 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"51376_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","volume":"128","author":"TW Kelley","year":"2007","unstructured":"Kelley, T. W., Pohlman, B., Elson, P. & Hsi, E. D. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am. J. Clin. Pathol. 128(6), 958\u2013965 (2007).","journal-title":"Am. J. Clin. Pathol."},{"key":"51376_CR5","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Macrophage polarization: Different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 10, 1084 (2019).","journal-title":"Front. Immunol."},{"issue":"7","key":"51376_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cells9071611","volume":"9","author":"A Sa\u0142kowska","year":"2020","unstructured":"Sa\u0142kowska, A. et al. Identification of novel molecular markers of human Th17 cells. Cells 9(7), 1611 (2020).","journal-title":"Cells"},{"issue":"5","key":"51376_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Leader, A. M. & Merad, M. MDSC: Markers, development, states, and unaddressed complexity. Immunity 54(5), 875\u2013884 (2021).","journal-title":"Immunity"},{"issue":"3","key":"51376_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11060-019-03187-y","volume":"143","author":"K Kaur","year":"2019","unstructured":"Kaur, K. et al. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres. J. Neurooncol. 143(3), 393\u2013403 (2019).","journal-title":"J. Neurooncol."},{"issue":"43","key":"51376_CR9","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102(43), 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"51376_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/1078-0432.CCR-19-2356","volume":"26","author":"S Luminari","year":"2020","unstructured":"Luminari, S. et al. A gene expression-based model to predict metabolic response after two courses of ABVD in Hodgkin lymphoma patients. Clin. Cancer Res. 26(2), 373\u2013383 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"51376_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11010-008-9923-1","volume":"321","author":"AH Campos","year":"2009","unstructured":"Campos, A. H., Aldred, V. L., Ribeiro, K. C., Vassallo, J. & Soares, F. A. Role of immunoexpression of nitric oxide synthases by Hodgkin and Reed-Sternberg cells on apoptosis deregulation and on clinical outcome of classical Hodgkin lymphoma. Mol. Cell Biochem. 321(1\u20132), 95\u2013102 (2009).","journal-title":"Mol. Cell Biochem."},{"issue":"4","key":"51376_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/ijlh.13559","volume":"43","author":"\u015e \u015eumnu","year":"2021","unstructured":"\u015eumnu, \u015e et al. Serum calprotectin (S100A8\/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma. Int. J. Lab. Hematol. 43(4), 638\u2013644 (2021).","journal-title":"Int. J. Lab. Hematol."},{"key":"51376_CR13","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.2147\/IJGM.S341557","volume":"14","author":"Z Kuang","year":"2021","unstructured":"Kuang, Z., Tu, J. & Li, X. Combined identification of novel markers for diagnosis and prognostic of classic Hodgkin lymphoma. Int. J. Gen. Med. 14, 9951\u20139963 (2021).","journal-title":"Int. J. Gen. Med."},{"issue":"2","key":"51376_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2005-12-5125","volume":"108","author":"A Sanchez-Aguilera","year":"2006","unstructured":"Sanchez-Aguilera, A. et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108(2), 662\u2013668 (2006).","journal-title":"Blood"},{"issue":"6","key":"51376_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/bjd\/ljad061","volume":"188","author":"R Alonso-Alonso","year":"2023","unstructured":"Alonso-Alonso, R. et al. NanoString analysis of mycosis fungoides reveals individual molecular identity. Br. J. Dermatol. 188(6), 812\u2013814 (2023).","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"51376_CR16","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.3390\/cancers14071772","volume":"14","author":"MA Timmins","year":"2022","unstructured":"Timmins, M. A. & Ringshausen, I. Transforming growth factor-beta orchestrates tumour and bystander cells in B-cell non-Hodgkin lymphoma. Cancers 14(7), 1772 (2022).","journal-title":"Cancers"},{"issue":"8","key":"51376_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/bloodadvances.2022007849","volume":"7","author":"AE Au","year":"2023","unstructured":"Au, A. E. et al. Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels. Blood Adv. 7(8), 1560\u20131571 (2023).","journal-title":"Blood Adv."},{"issue":"10","key":"51376_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer, M. G. M. et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J. Clin. Oncol. 36(10), 942\u2013950 (2018).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"51376_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/10428190400013712","volume":"46","author":"D Aldinucci","year":"2005","unstructured":"Aldinucci, D. et al. The role of interleukin-3 in classical Hodgkin\u2019s disease. Leuk. Lymphoma 46(3), 303\u2013311 (2005).","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"51376_CR20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0161-5890(02)00004-4","volume":"38","author":"MC Gingras","year":"2002","unstructured":"Gingras, M. C., Lapillonne, H. & Margolin, J. F. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol. Immunol. 38(11), 817\u2013824 (2002).","journal-title":"Mol. Immunol."},{"issue":"5","key":"51376_CR21","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1189\/jlb.0404259","volume":"76","author":"A Kiani","year":"2004","unstructured":"Kiani, A. et al. Expression and regulation of NFAT (nuclear factors of activated T cells) in human CD34+ cells: down-regulation upon myeloid differentiation. J. Leukoc. Biol. 76(5), 1057\u20131065 (2004).","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"51376_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano, A. et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br. J. Haematol. 168(5), 689\u2013700 (2015).","journal-title":"Br. J. Haematol."},{"issue":"12","key":"51376_CR23","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.3390\/cancers12123757","volume":"12","author":"I Ferrarini","year":"2020","unstructured":"Ferrarini, I., Rigo, A., Visco, C., Krampera, M. & Vinante, F. The evolving knowledge on T and NK cells in classic Hodgkin lymphoma: Insights into novel subsets populating the immune microenvironment. Cancers 12(12), 3757 (2020).","journal-title":"Cancers"},{"issue":"6","key":"51376_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2012.43.4589","volume":"31","author":"DW Scott","year":"2013","unstructured":"Scott, D. W. et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J. Clin. Oncol. 31(6), 692\u2013700 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"51376_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1080\/10428190500220654","volume":"46","author":"T Alvaro-Naranjo","year":"2005","unstructured":"Alvaro-Naranjo, T. et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin\u2019s lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk. Lymphoma 46(11), 1581\u20131591 (2005).","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"51376_CR26","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10428194.2016.1239263","volume":"58","author":"S Alonso-\u00c1lvarez","year":"2017","unstructured":"Alonso-\u00c1lvarez, S. et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup\/>. Leuk. Lymphoma 58(5), 1144\u20131152 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"51376_CR27","doi-asserted-by":"publisher","first-page":"5254911","DOI":"10.1155\/2022\/5254911","volume":"2022","author":"X Cheng","year":"2022","unstructured":"Cheng, X. et al. Systematic pan-cancer analysis of KLRB1 with prognostic value and immunological activity across human tumors. J. Immunol. Res. 2022, 5254911 (2022).","journal-title":"J. Immunol. Res."},{"key":"51376_CR28","doi-asserted-by":"publisher","first-page":"626818","DOI":"10.3389\/fonc.2021.626818","volume":"11","author":"B Apollonio","year":"2021","unstructured":"Apollonio, B., Ioannou, N., Papazoglou, D. & Ramsay, A. G. Understanding the immune-stroma microenvironment in B cell malignancies for effective immunotherapy. Front. Oncol. 11, 626818 (2021).","journal-title":"Front. Oncol."},{"issue":"10","key":"51376_CR29","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/leu.2012.81","volume":"26","author":"H Mizuno","year":"2012","unstructured":"Mizuno, H. et al. Mast cells promote the growth of Hodgkin\u2019s lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia 26(10), 2269\u20132276 (2012).","journal-title":"Leukemia"},{"issue":"11","key":"51376_CR30","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1128\/MCB.01932-05","volume":"26","author":"PD Simoncic","year":"2006","unstructured":"Simoncic, P. D. et al. T-cell protein tyrosine phosphatase (Tcptp) is a negative regulator of colony-stimulating factor 1 signaling and macrophage differentiation. Mol. Cell. Biol. 26(11), 4149\u20134160 (2006).","journal-title":"Mol. Cell. Biol."},{"issue":"16","key":"51376_CR31","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","volume":"122","author":"P Greaves","year":"2013","unstructured":"Greaves, P. et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122(16), 2856\u20132863 (2013).","journal-title":"Blood"},{"issue":"14","key":"51376_CR32","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1080\/10428194.2019.1636983","volume":"60","author":"I Ferrarini","year":"2019","unstructured":"Ferrarini, I., Rigo, A., Zam\u00f2, A. & Vinante, F. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. Leuk. Lymphoma 60(14), 3395\u20133405 (2019).","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"51376_CR33","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1158\/1078-0432.CCR-04-1869","volume":"11","author":"T Alvaro","year":"2005","unstructured":"Alvaro, T. et al. Outcome in Hodgkin\u2019s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11(4), 1467\u20131473 (2005).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"51376_CR34","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1182\/blood-2010-02-270009","volume":"116","author":"B Sanchez-Espiridion","year":"2010","unstructured":"Sanchez-Espiridion, B. et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116(8), E12\u2013E17 (2010).","journal-title":"Blood"},{"issue":"23","key":"51376_CR35","first-page":"2059","volume":"134","author":"SS Patel","year":"2019","unstructured":"Patel, S. S. et al. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood 134(23), 2059\u20132069 (2019).","journal-title":"Blood"},{"issue":"4","key":"51376_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/cancers12040877","volume":"12","author":"K Karihtala","year":"2020","unstructured":"Karihtala, K. et al. Prognostic impact of tumor-associated macrophages on survival is checkpoint dependent in classical Hodgkin lymphoma. Cancers 12(4), 877 (2020).","journal-title":"Cancers"},{"key":"51376_CR37","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3389\/fonc.2020.01008","volume":"10","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Identification of immune-related prognostic biomarkers based on the tumor microenvironment in 20 malignant tumor types with poor prognosis. Front. Oncol. 10, 1008 (2020).","journal-title":"Front. Oncol."},{"issue":"8","key":"51376_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","volume":"132","author":"FZ Cader","year":"2018","unstructured":"Cader, F. Z. et al. Mass cytometry of Hodgkin lymphoma reveals a CD4. Blood 132(8), 825\u2013836 (2018).","journal-title":"Blood"},{"issue":"3","key":"51376_CR39","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","volume":"10","author":"T Aoki","year":"2020","unstructured":"Aoki, T. et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov. 10(3), 406\u2013421 (2020).","journal-title":"Cancer Discov."},{"issue":"1","key":"51376_CR40","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1365-2141.2002.03575.x","volume":"118","author":"GM Reynolds","year":"2002","unstructured":"Reynolds, G. M. et al. Interleukin 6 expression by Hodgkin\/Reed-Sternberg cells is associated with the presence of \u201cB\u201d symptoms and failure to achieve complete remission in patients with advanced Hodgkin\u2019s disease. Br. J. Haematol. 118(1), 195\u2013201 (2002).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"51376_CR41","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","volume":"5","author":"AR Gholiha","year":"2021","unstructured":"Gholiha, A. R. et al. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma. Blood Adv. 5(6), 1671\u20131681 (2021).","journal-title":"Blood Adv."},{"issue":"12","key":"51376_CR42","doi-asserted-by":"publisher","first-page":"e114345","DOI":"10.1371\/journal.pone.0114345","volume":"9","author":"CS Tudor","year":"2014","unstructured":"Tudor, C. S. et al. Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma. PLoS One 9(12), e114345 (2014).","journal-title":"PLoS One"},{"issue":"3","key":"51376_CR43","first-page":"827","volume":"201","author":"V Shankaran","year":"2018","unstructured":"Shankaran, V. et al. Pillars article: IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. J. Immunol. 201(3), 827\u2013831 (2018).","journal-title":"J. Immunol."},{"issue":"6","key":"51376_CR44","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167(6), 1540\u201354.e12 (2016).","journal-title":"Cell"},{"issue":"19","key":"51376_CR45","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1038\/sj.onc.1205418","volume":"21","author":"E Devilard","year":"2002","unstructured":"Devilard, E. et al. Gene expression profiling defines molecular subtypes of classical Hodgkin\u2019s disease. Oncogene 21(19), 3095\u20133102 (2002).","journal-title":"Oncogene"},{"issue":"22","key":"51376_CR46","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood.V114.22.1560.1560","volume":"114","author":"F Mestre","year":"2009","unstructured":"Mestre, F. et al. Expression of COX-2 is an independent unfavourable prognostic factor in Hodgkin lymphoma treated with ABVD with or without radiotherapy. Blood 114(22), 624\u2013625 (2009).","journal-title":"Blood"},{"issue":"7015","key":"51376_CR47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature03096","volume":"432","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432(7015), 332\u2013337 (2004).","journal-title":"Nature"},{"issue":"Pt B","key":"51376_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ishii","year":"2016","unstructured":"Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Deliv. Rev. 99(Pt B), 186\u2013196 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"51376_CR49","first-page":"1889","volume":"9","author":"TX Huang","year":"2019","unstructured":"Huang, T. X., Guan, X. Y. & Fu, L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. Am. J. Cancer Res. 9(9), 1889\u20131904 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"51376_CR50","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fimmu.2018.01358","volume":"9","author":"B D\u00f6rsam","year":"2018","unstructured":"D\u00f6rsam, B. et al. Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype. Front. Immunol. 9, 1358 (2018).","journal-title":"Front. Immunol."},{"key":"51376_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/hon.118_2880","author":"K Karihtala","year":"2021","unstructured":"Karihtala, K. et al. Characterization of cancer associated fibroblasts in classical Hodgkin lymphoma. Hematol. Oncol. https:\/\/doi.org\/10.1002\/hon.118_2880 (2021).","journal-title":"Hematol. Oncol."},{"issue":"5","key":"51376_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood.2022015414","volume":"141","author":"LV Cappelli","year":"2023","unstructured":"Cappelli, L. V. et al. Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities. Blood 141(5), 503\u2013518 (2023).","journal-title":"Blood"},{"issue":"242","key":"51376_CR53","doi-asserted-by":"publisher","first-page":"242ra84","DOI":"10.1126\/scitranslmed.3008455","volume":"6","author":"L Xu","year":"2014","unstructured":"Xu, L. et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med. 6(242), 242ra84 (2014).","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"51376_CR54","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","volume":"126","author":"AT Franco","year":"2015","unstructured":"Franco, A. T., Corken, A. & Ware, J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood 126(5), 582\u2013588 (2015).","journal-title":"Blood"},{"issue":"7","key":"51376_CR55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/09537104.2016.1171302","volume":"27","author":"CE Holmes","year":"2016","unstructured":"Holmes, C. E. et al. Platelet phenotype changes associated with breast cancer and its treatment. Platelets 27(7), 703\u2013711 (2016).","journal-title":"Platelets"},{"issue":"5","key":"51376_CR56","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/ijc.20657","volume":"113","author":"A Janowska-Wieczorek","year":"2005","unstructured":"Janowska-Wieczorek, A. et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 113(5), 752\u2013760 (2005).","journal-title":"Int. J. Cancer"},{"issue":"16","key":"51376_CR57","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu, X. R., Yousef, G. M. & Ni, H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 131(16), 1777\u20131789 (2018).","journal-title":"Blood"},{"issue":"32","key":"51376_CR58","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","volume":"35","author":"FC Chan","year":"2017","unstructured":"Chan, F. C. et al. Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical Hodgkin lymphoma. J. Clin. Oncol. 35(32), 3722\u20133733 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"51376_CR59","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/bjh.16777","volume":"190","author":"L Calvente","year":"2020","unstructured":"Calvente, L. et al. Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma. Br. J. Haematol. 190(6), 864\u2013868 (2020).","journal-title":"Br. J. Haematol."}],"updated-by":[{"DOI":"10.1038\/s41598-024-78993-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51376-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51376-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T07:09:53Z","timestamp":1731654593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51376-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51376-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-024-78993-0","URL":"https:\/\/doi.org\/10.1038\/s41598-024-78993-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"710"}}